In Vivo CAR-T Patents

In vivo CAR-T patents cover targeted-LNP-mRNA delivery innovations; T-cell-targeted viral-vector innovations; in-situ CAR-construct and reprogramming innovations; and dosing and safety innovations — with IP held by in-vivo-reprogramming startups racing to make CAR-T without ex vivo manufacturing. MAJOR IN-VIVO CAR-T PATENT HOLDERS: CAPSTAN THERAPEUTICS (Novartis): targeted lipid nanoparticles LNPs that deliver CAR-encoding mRNA specifically to T cells in the body (CD8/CD5-targeted LNPs, transient CAR expression), built on University of Pennsylvania work (Weissman/Epstein/June) — a leading targeted-LNP in-vivo CAR-T estate. UMOJA BIOPHARMA: VivoVec — a T-cell-targeted lentiviral vector that integrates a CAR in situ (with an integrated proliferation/selection module), generating durable CAR-T inside the patient. INTERIUS BIOTHERAPEUTICS: in vivo lentiviral delivery targeting T cells. EsoBiotec (AstraZeneca): the ENaBL in-situ lentiviral platform. OTHERS: Orna Therapeutics (circular-RNA in vivo), Myeloid Therapeutics (in vivo mRNA), and the foundational Penn LNP/T-cell-targeting and CAR-T holders. The premise: conventional CAR-T requires extracting a patient's T cells, engineering and expanding them ex vivo (weeks, ~$0.5M, lymphodepletion), and reinfusing — in vivo CAR-T reprograms T cells INSIDE the body with a single dose, potentially democratizing access. Targeted LNP-mRNA delivery and T-cell-targeted viral vectors are the core in-vivo CAR-T patent domains.

T-cell-targeting ligand and LNP innovations; CAR-mRNA and payload innovations; transient-expression and re-dosing innovations; and safety and biodistribution innovations represent core targeted-LNP in-vivo CAR-T patent domains — and delivering CAR mRNA selectively to T cells in vivo is the central, hard problem. TARGETING-LIGAND / LNP PATENTS: lipid nanoparticles decorated with a T-cell-targeting moiety — anti-CD8, anti-CD5, anti-CD3, or anti-CD7 antibodies/fragments conjugated to the LNP surface to direct uptake to T cells (avoiding liver, the default LNP destination — re-targeting away from the liver is the key technical advance), plus ionizable-lipid composition tuned for T-cell delivery and endosomal escape in lymphocytes. CAR-mRNA PATENTS: the CAR-encoding mRNA (transiently expressed — a safety feature, since the CAR fades, unlike permanent integration), mRNA optimization (nucleoside modification, UTRs), and the CAR construct itself. TRANSIENT / RE-DOSING PATENTS: transient CAR expression (self-limiting, addressing cytokine-release-syndrome and persistence-safety concerns) and re-dosing regimens (since the effect wanes). SAFETY / BIODISTRIBUTION PATENTS: off-target/off-tissue avoidance, controlling on-target dose, and immune response to the LNP. The T-cell-targeting ligand + liver-detargeted LNP and the transient CAR-mRNA are the highest-value targeted-LNP in-vivo CAR-T IP — and they share heritage with mRNA-vaccine LNP IP (FTO consideration).

T-cell-targeted lentiviral/AAV-vector innovations; pseudotyping and envelope-engineering innovations; in-situ integration and selection innovations; and durability innovations represent additional in-vivo CAR-T patent domains — and engineering a virus to integrate a CAR specifically in T cells in vivo is the durable-expression alternative to transient mRNA. TARGETED-VECTOR PATENTS: lentiviral (and AAV) vectors engineered to transduce T cells specifically in the body — pseudotyping/envelope engineering (displaying a T-cell-targeting ligand, e.g. anti-CD3/CD8, on the viral envelope so the vector binds and enters only T cells — Umoja VivoVec, Interius), and vector designs minimizing off-target transduction. IN-SITU INTEGRATION / SELECTION PATENTS: integrating the CAR (durable expression, unlike transient mRNA), plus in-situ proliferation/selection modules (a built-in switch to expand the CAR-T after transduction — Umoja's rapamycin-activated cytokine receptor), and safety switches. DURABILITY PATENTS: achieving durable CAR-T persistence from a single in vivo dose, versus the transient mRNA approach. SHARED CAR / FTO PATENTS: the CAR construct and costimulatory domains still implicate the underlying CAR-T patent estate (UPenn/MSK/NCI — see CAR-T cell therapy), so in vivo CAR-T must clear that IP too. Engineered T-cell-targeting viral envelopes and in-situ selection/expansion are the highest-value viral in-vivo CAR-T IP — and they avoid the ex vivo manufacturing moat that defines conventional CAR-T.

In vivo CAR-T startup IP strategy must navigate Capstan targeted-LNP patents, Umoja/Interius/EsoBiotec targeted-vector patents, the underlying CAR-T construct estate (UPenn/MSK/NCI costimulatory-domain patents — your CAR still uses these), mRNA and LNP IP (shared with mRNA vaccines — Acuitas/Arbutus/Genevant), Penn foundational targeted-LNP work, and a landscape where the delivery (targeting T cells in vivo) is the novel, defensible asset; understand that in vivo CAR-T's value is eliminating ex vivo manufacturing (the conventional CAR-T moat), so the durable IP is in the T-CELL-TARGETED DELIVERY (LNP ligand + liver-detargeting, or viral envelope), the transient-vs-durable expression approach, and in-situ selection, and that you must ALSO clear CAR-construct and LNP/vector FTO; identify whitespace in T-cell-targeting ligands, liver-detargeted LNPs, T-cell-targeted viral envelopes, transient-safety designs, and re-dosing. IN-VIVO CAR-T STARTUP IP STRATEGY: T-CELL-TARGETED DELIVERY IS THE NOVEL IP — BUT CLEAR CAR + LNP/VECTOR FTO: the breakthrough is delivering the CAR to T cells IN VIVO (eliminating ex vivo manufacturing) — patent the T-cell-targeting ligand + liver-detargeted LNP (or the T-cell-targeted viral envelope) and the in-situ approach; but your CAR construct still implicates UPenn/MSK/NCI CAR-T IP and your LNP/vector implicates mRNA-vaccine/Acuitas IP — secure that FTO; LIVER-DETARGETING AND T-CELL-SELECTIVE LNPs ARE HIGHEST-VALUE: redirecting LNPs away from the liver to T cells (anti-CD8/CD5 targeting) is the central, hard, valuable invention; TARGETED VIRAL ENVELOPES AND IN-SITU SELECTION ARE THE DURABLE-EXPRESSION WHITESPACE: pseudotyped T-cell-targeting lentivirus + in-situ proliferation/selection (Umoja-style) is the alternative to transient mRNA; TRANSIENT-EXPRESSION SAFETY IS A DIFFERENTIATING DESIGN: self-limiting CAR-mRNA addresses CRS/persistence safety and enables re-dosing — patentable design and regimen IP; ELIMINATING EX VIVO MANUFACTURING IS THE BUSINESS THESIS: the value is democratizing CAR-T (no apheresis, no weeks, no lymphodepletion, far lower cost) — protect the in vivo delivery that enables it; WHEN TO PATENT: NOVEL DELIVERY/SYSTEM WITH MEASURED PERFORMANCE: file once a system shows measured results (T-cell-targeting selectivity + in vivo CAR-T generation/expansion + transience/durability + efficacy + safety/CRS) vs. ex vivo CAR-T baselines — measured targeting selectivity, in vivo CAR-T yield, persistence, and safety are the critical in-vivo CAR-T IP metrics; KEY FTO CHECKLIST: Capstan targeted LNP CD8/CD5 anti-T-cell ligand + CAR mRNA transient (Penn); Umoja VivoVec T-cell-targeted lentiviral + rapamycin-activated selection; Interius/EsoBiotec in vivo lentiviral; liver-detargeting ionizable-lipid LNP; T-cell-targeted pseudotyped envelope; CAR construct/costimulatory (UPenn/MSK/NCI CAR-T FTO); mRNA/LNP FTO (Acuitas/Arbutus); transient-expression safety + re-dosing.